Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 11/20 | 0.57 |
| ▸ | BCHE | P06276 | 8/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302730 | 0.86 | HTT (0.46) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL30711781 | 0.86 | HTT (0.46) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL31606945 | 0.86 | ACHE (0.60) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL22911500 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL9500076 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL12778520 | 0.83 | LMNA (0.61) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL25605953 | 0.83 | ALDH1A1 (0.43) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL765839 | 0.81 | HTT (0.41) | SMN1; SMN2HTTACHEBCHEL3MBTL1 | |
| SCHEMBL11951551 | 0.81 | FDPS (0.52) | ACHEBCHEALDH1A1MAPT | |
| SCHEMBL29654960 | 0.80 | ACHE (0.63) | SMN1; SMN2HTTACHEBCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | SMN1; SMN2 2287/4885HTT 2890/4885ACHE 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.